BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/27/2019 7:04:05 AM | Browse: 844 | Download: 1054
 |
Received |
|
2018-09-27 03:36 |
|
Peer-Review Started |
|
2018-09-27 04:25 |
|
To Make the First Decision |
|
2018-10-17 01:28 |
|
Return for Revision |
|
2018-10-19 04:32 |
|
Revised |
|
2018-11-14 01:09 |
|
Second Decision |
|
2018-12-29 02:13 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-01-01 05:56 |
|
Articles in Press |
|
2019-01-01 05:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-01-24 09:03 |
|
Publish the Manuscript Online |
|
2019-01-27 07:04 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Brianna J Shinn, Aaron Martin, Robert M Coben, Mitchell I Conn, Jorge Prieto, Howard Kroop, Anthony J DiMarino and Hie-Won Hann |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hie-Won Hann, Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, 1025 Walnut Street, Philadelphia, PA 19107, United States. hie-won.hann@jefferson.edu |
| Key Words |
Hepatitis B; Hepatocellular carcinoma; Antiviral therapy; Persistent Risk for hepatocellular carcinoma; Tumor ablation |
| Core Tip |
Despite the advances in the management of hepatitis B virus (HBV) infection and HBV-associated hepatocellular carcinoma (HCC), the risk for new, subsequent new and recurrent HCC persists even after over a decade of antiviral therapy and initial tumor ablation. This is due to the inability of the current antiviral therapy to eliminate the cccDNA from the hepatocyte nucleus. There is a great need for an HBV cure drug. |
| Publish Date |
2019-01-27 07:04 |
| Citation |
Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol 2019; 11(1): 65-73 |
| URL |
https://www.wjgnet.com/1948-5182/full/v11/i1/65.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v11.i1.65 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
